Harbour BioMed (HBM), a China-US-Dutch biopharma, was approved to start US clinical trials of its next-gen CLTA-4 antibody in patients with solid tumors. The company discovered HBM4003, a fully human monoclonal heavy chain only antibody (HCAb), using its Harbour Mice® technology. The trial will evaluate the safety, tolerability, pharmacokinetics, and anti-tumor activity of HBM4003 as a single agent. The US approval was the second in two days for the company. Yesterday, Harbour announced approval for a US IND of its PD-L1 candidate. More details.... Share this with colleagues: // //